Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

H.C. Wainwright reiterates Buy on Anixa stock, $6 target on trial data

H.C. Wainwright reiterates Buy on Anixa stock, $6 target on trial data

H.C. Wainwright has reaffirmed its Buy rating and $6 price target for Anixa Biosciences (NASDAQ:ANIX) following promising clinical trial results. Currently trading at $2.95, the stock presents significant upside potential. Consensus among analysts remains Strong Buy, with price targets ranging from $6 to $14. The firm's decision to maintain its rating followed Anixa's announcement of a patient in its Phase 1 dose-escalating trial of lira-cel, an FSHR-targeted CAR-T therapy for recurrent ovarian cancer.

This patient demonstrated stable disease 90 days post-treatment, marking the first such response in the trial. The dose used was the highest level evaluated thus far, with no dose-limiting toxicities reported in any patients. A majority of patients have shown survival beyond one year following treatment. Anixa's financial health is robust, with a current ratio of 8.54 and more cash than debt on its balance sheet.

The company anticipates further updates from the trial in the coming months. Recently, Anixa received Patent Number 2020221280 from IP Australia, protecting its breast cancer vaccine technology in Australia until 2040. The company has also initiated the first patient in the fifth cohort of its Phase 1 CAR-T therapy trial for recurrent ovarian cancer, conducted at the Moffitt Cancer Center. This therapy targets the follicle stimulating hormone receptor, present on ovarian cancer cells.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at investing.com →

More in Finance & Markets

More from Tuesday 6 October →